December 27th 2020
By Tony Hagen
In part 2 of this year-end feature, we look at the most-read biosimilar stories of the second half of 2020.
December 24th 2020
The top stories in biosimilars for 2020 encompassed biosimilar approvals and launches, the coronavirus disease 2019 pandemic, and the FDA's challenge to stay on top of the rapidly changing health care landscape.
December 19th 2020
In the EU-5 group of countries, biosimilar awareness is poor, hindering uptake of these potentially cost-saving medicines, a white paper states.
December 16th 2020
Samsung Bioepis hopes to gain regulatory approval for a denosumab biosimilar referencing Prolia. The trial will focus on women with postmenopausal osteoporosis.
December 10th 2020
Two studies of trastuzumab biosimilars have improved understanding of these medicines as monotherapy and in combination with other agents in metastatic breast cancer.
December 8th 2020
A high overall response rate of 93% was observed for patients with immune thrombocytopenic purpura who received romiplostim biosimilar.
December 1st 2020
The wearable injector has a failure rate that adds hospitalization costs; therefore, biosimilar pegfilgrastim may hold cost advantages, investigators conclude.
November 30th 2020
Biosimilar suffixes were intended to help with pharmacovigilance, but they are not widely understood.
November 24th 2020
By Skylar Jeremias
Minute differences between biosimilars and reference products are not considered “clinically meaningful,” but these differences are exploitable when it comes to addressing allergies related to originator products.
November 23rd 2020
Pfizer aims to begin marketing Nyvepria in the European Union in the first quarter of 2021.
